Last reviewed · How we verify

LMWH+Folic acid

Omar Mamdouh Shaaban · FDA-approved active Small molecule

LMWH+Folic acid is a Anticoagulant combination with vitamin supplement Small molecule drug developed by Omar Mamdouh Shaaban. It is currently FDA-approved for Thromboprophylaxis in pregnancy or thrombophilic disorders, Prevention of venous thromboembolism with folate supplementation. Also known as: (Clexane, Sanofi Aventis, Paris, France).

This combination product uses low-molecular-weight heparin (LMWH) to prevent blood clots and folic acid to support cellular function and reduce homocysteine levels.

This combination product uses low-molecular-weight heparin (LMWH) to prevent blood clots and folic acid to support cellular function and reduce homocysteine levels. Used for Thromboprophylaxis in pregnancy or thrombophilic disorders, Prevention of venous thromboembolism with folate supplementation.

At a glance

Generic nameLMWH+Folic acid
Also known as(Clexane, Sanofi Aventis, Paris, France)
SponsorOmar Mamdouh Shaaban
Drug classAnticoagulant combination with vitamin supplement
TargetFactor Xa, Thrombin (LMWH component); Dihydrofolate reductase (folic acid component)
ModalitySmall molecule
Therapeutic areaCardiovascular / Hematology
PhaseFDA-approved

Mechanism of action

LMWH inhibits thrombin and Factor Xa, preventing thrombosis through anticoagulation. Folic acid is a B vitamin essential for DNA synthesis and homocysteine metabolism, potentially reducing cardiovascular risk. The combination may be used in pregnancy or thrombophilic conditions where both anticoagulation and folate supplementation are therapeutically beneficial.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LMWH+Folic acid

What is LMWH+Folic acid?

LMWH+Folic acid is a Anticoagulant combination with vitamin supplement drug developed by Omar Mamdouh Shaaban, indicated for Thromboprophylaxis in pregnancy or thrombophilic disorders, Prevention of venous thromboembolism with folate supplementation.

How does LMWH+Folic acid work?

This combination product uses low-molecular-weight heparin (LMWH) to prevent blood clots and folic acid to support cellular function and reduce homocysteine levels.

What is LMWH+Folic acid used for?

LMWH+Folic acid is indicated for Thromboprophylaxis in pregnancy or thrombophilic disorders, Prevention of venous thromboembolism with folate supplementation.

Who makes LMWH+Folic acid?

LMWH+Folic acid is developed and marketed by Omar Mamdouh Shaaban (see full Omar Mamdouh Shaaban pipeline at /company/omar-mamdouh-shaaban).

Is LMWH+Folic acid also known as anything else?

LMWH+Folic acid is also known as (Clexane, Sanofi Aventis, Paris, France).

What drug class is LMWH+Folic acid in?

LMWH+Folic acid belongs to the Anticoagulant combination with vitamin supplement class. See all Anticoagulant combination with vitamin supplement drugs at /class/anticoagulant-combination-with-vitamin-supplement.

What development phase is LMWH+Folic acid in?

LMWH+Folic acid is FDA-approved (marketed).

What are the side effects of LMWH+Folic acid?

Common side effects of LMWH+Folic acid include Bleeding, Thrombocytopenia, Injection site reactions, Gastrointestinal upset (folic acid).

What does LMWH+Folic acid target?

LMWH+Folic acid targets Factor Xa, Thrombin (LMWH component); Dihydrofolate reductase (folic acid component) and is a Anticoagulant combination with vitamin supplement.

Related